ESR1 and neoplasm: On the other hand, hormone receptor-positive (HR+) or estrogen receptor-positive (ER+) BCs often exhibit minimal immune infiltration, requiring different approaches to induce immune activation, such as targeting tumor-associated macrophages (TAMs) or using cytokine-based therapies to recruit immune cells [24].